Gufic Biosciences Limited has informed the Exchange regarding Board meeting held on August 13, 2025.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences' Board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose about 11.9% year-on-year to Rs. 22,691 lakhs, but net profit dropped sharply by roughly 42% to Rs. 1,207 lakhs (from Rs. 2,086 lakhs). Consolidated revenue grew about 10.3% to Rs. 22,372 lakhs while consolidated net profit declined around 37% to Rs. 1,307 lakhs. Basic EPS fell from Rs. 2.08 to Rs. 1.20 on a standalone basis. The Board also re-appointed Poddar & Co. as Cost Auditors for FY 2025-26 and Mittal Agarwal & Co. as Statutory Auditors for a second 5-year term till the 2030 AGM. The statutory auditor issued a clean limited review report with no qualifications or emphasis of matter.
Despite decent topline growth, the sharp ~40% drop in profits points to significant margin compression, which could weigh negatively on the stock in the short term. Shareholders should watch for management commentary on rising input costs or one-off expenses driving the profit decline.